Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in China
723 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleTislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Where
- Nanjing, Taiyuan, Wuhan
- Age
- 18 years to 75 years
- People
- 140
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT05687357 - Phase 3Taking peopleStudy of Comparing of With and Without Sequential Therapy of S-1
- Where
- Hanzhou
- Age
- 18 years to 75 years
- People
- 70
- Run by
- Zhejiang University
See details and how to joinNCT05813015 - No phaseTaking peoplePaclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 95
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT04047953 - No phaseTaking peopleEffect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 210
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05800054 - No phaseTaking peopleNeoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05740995 - No phaseTaking peopleComparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
- Where
- Nanjing
- Age
- 18 years to 70 years
- People
- 1,216
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05775419 - Phase 2Taking peopleThe Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 38
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT05536102 - No phaseTaking peoplePrediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- Where
- Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Chinese Academy of Sciences
See details and how to joinNCT05722275 - Phase 2Taking peopleAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Where
- Nanchang
- Age
- 18 years and over
- People
- 30
- Run by
- Jiangxi Provincial Cancer Hospital
See details and how to joinNCT05252078 - Phase 2Not yet taking people in ChinaPembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 54
- Run by
- Peking University
See details and how to joinNCT05386056 - No phaseTaking peopleTreatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Shenzhen University General Hospital
See details and how to joinNCT05620732 - No phaseTaking peopleAjuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
- Where
- Jinan
- Age
- 25 years to 80 years
- People
- 200
- Run by
- The Second Hospital of Shandong University
See details and how to joinNCT04688801 - Phase 2Taking peopleClinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 68
- Run by
- Fujian Medical University
See details and how to joinNCT05618821 - Phase 3Not yet taking people in ChinaClinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 216
- Run by
- Fujian Medical University
See details and how to joinNCT05610332 - Phase 3Not yet taking people in ChinaSintilimab Plus NCT or NCRT Versus NCRT for ESCC
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 420
- Run by
- Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT05244798 - Phase 3Taking peopleNeo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 400
- Run by
- Henan Cancer Hospital
See details and how to joinNCT04280822 - No phaseTaking peopleLaparoscopic vs Open Total Gastrectomy for Gastric Cancer
- Where
- Shanghai
- Age
- 20 years to 80 years
- People
- 600
- Run by
- Fudan University
See details and how to joinNCT05537129 - Phase 2Not yet taking people in ChinaClinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 203
- Run by
- Fujian Medical University
See details and how to joinNCT05524974 - Phase 2Taking peopleWatch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
- Where
- Hanzhou, Ningbo
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT05507411 - Phase 2Not yet taking people in ChinaNeoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 26
- Run by
- Peking University People's Hospital
See details and how to joinNCT05505461 - Phase 3Taking peopleNeoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
- Where
- Zhengzhou
- Age
- 18 years to 70 years
- People
- 456
- Run by
- Henan Cancer Hospital
See details and how to joinNCT04138212 - No phaseTaking peopleImmune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 200
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT05392413 - Phase 2/3Taking peopleNeoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 176
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT04973306 - No phaseNot yet taking people in ChinaTwo-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 323
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05420480 - Phase 3Taking peoplePembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 342
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT04807673